High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa
- 1 May 2020
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (5) , 1094-1101
Abstract
No abstract availableKeywords
Funding Information
- Albert Einstein College of Medicine (T32 GM007288)
This publication has 32 references indexed in Scilit:
- Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational studyBritish Journal of Dermatology, 2013
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational studyRheumatology International, 2011
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1βBritish Journal of Dermatology, 2011
- Obesity and psoriasis: body weight and body mass index influence the response to biological treatmentJournal of the European Academy of Dermatology and Venereology, 2011
- Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgarisBritish Journal of Dermatology, 2011
- Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STUREScandinavian Journal of Rheumatology, 2007
- Epidemiological Aspects of Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2006
- Clinically Important Changes in Acute Pain Outcome MeasuresJournal of Pain and Symptom Management, 2003
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002